(30), who found a significant increase of CXCL2 (p = 0.047), CXCL3 (p = 0.013), CXCL6 (p = 0.012), CXCL8 (p = 0.01), CXCL9 (p = 0.026), CXCL14 (p = 1.49E−5), and CXCL16 (p = 0.003) in PAAD. Here, CXCL16 is linked to pancreatic adenocarcinoma.